Tcc denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for tcc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Total Contact Casting as "Not FDA-Approved" — and How to Appeal

A "not FDA-approved" denial for total contact casting (TCC) is almost always based on a misclassification. TCC is a casting procedure and a category of durable medical equipment, not a drug or biologic requiring FDA drug approval. The casting materials are FDA-cleared medical devices; the application procedure (CPT 29445) is a recognized medical service. If Humana has issued this denial, the appeal should directly challenge the legal and clinical basis of the determination.

## Why This Denial Is Appealable

FDA "approval" requirements apply to drugs and biologics under 21 U.S.C. §355 and §262. Medical devices used in TCC — casting tape, padding, stockinette — are regulated as Class I or Class II medical devices under FDA 510(k) clearance, not drug approval. The application procedure itself requires no FDA approval. A denial asserting TCC lacks "FDA approval" conflates device clearance with drug approval and misapplies the FDA framework. Furthermore, TCC is a well-established standard-of-care procedure endorsed by major wound-care and podiatric societies for its intended indication.

## Federal Appeal Framework

• Internal appeal (Level 1): File within 180 days. The appeal letter should specifically address the inapplicability of FDA drug-approval requirements to a casting procedure and DME.
• Expedited appeal: Available if active wound deterioration poses imminent risk.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals. An independent clinical reviewer is not bound by Humana's policy characterization and must apply the correct regulatory and clinical standard. Use the full ~4-month external-review window; do not delay.

## Documentation to Gather

1. Regulatory clarification: A written argument in the appeal letter citing the applicable FDA device-clearance framework for casting materials, distinguishing it from drug approval requirements. 2. Clinical standard-of-care documentation: Reference to the wound-care and vascular/podiatric professional society guidance recognizing TCC as a standard procedure for the relevant indication. 3. Diagnosis and wound chart notes: Confirming the patient's wound type, grade, and clinical characteristics that support TCC selection. 4. Prescriber medical-necessity letter: From a wound-care-credentialed provider explaining the clinical rationale and the regulatory status of TCC materials and the procedure. 5. Prior-treatment record: Dates and outcomes of alternative offloading modalities attempted.

## Criteria-Mapping Structure

Address both the regulatory misapplication and the clinical-necessity elements in parallel:

| Denial Basis | Appeal Response | |---|---| | "Not FDA-approved" assertion | TCC is a device/procedure; FDA 510(k)-cleared materials; no drug approval required | | Coverage criteria — wound type | Chart note confirming wound classification | | Coverage criteria — provider qualification | Credential documentation | | Coverage criteria — prior offloading failure | Prior-treatment log with dates and outcomes |

Request that Humana identify the specific FDA approval statute or regulatory requirement it applied and explain how that requirement governs a casting procedure. An insurer cannot sustain a "not FDA-approved" denial for a service that is not subject to FDA drug approval.